Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for hepatitis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hepatitis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on hepatitis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement | The Medical Journal of Australia mja-search search Use the for more specific terms. Title contains Body contains Date range from Date range to Article type Author's surname Volume First page doi: 10.5694/mja__.______ Search Reset (...) close Individual Login Purchase options Connect person_outline Login keyboard_arrow_down Individual Login Purchase options menu search Advertisement close Hepatitis B management during immunosuppression for haematological and solid organ malignancies: an Australian consensus statement Joseph Doyle, Michelle Raggatt, Monica Slavin, Sue‐Anne McLachlan, Simone I Strasser, Joseph J Sasadeusz, Jessica Howell, Krispin Hajkowicz, Harshal Nandurkar, Anna Johnston, Narin Bak and Alexander J Thompson Med J
Screening for hepatitis C 1 Translation of the key statement of the final report S16-04 Screening auf Hepatitis C (Version 1.0; Status: 19 September 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. S16-04 Screening for hepatitis C 1 Extract of final report S16-04 Version 1.0 (...) Screening for hepatitis C 19 September 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Screening for hepatitis C Commissioning agency: Federal Joint Committee Commission awarded on: 22 September 2016 Internal Commission No.: S16-04 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1
Options for national testing and surveillance for hepatitis E virus in the EU/EEA TECHNICAL REPORT Options for national testing and surveillance for hepatitis E virus in the EU/EEA Operational guidance www.ecdc.europa.euECDC TECHNICAL REPORT Options for national testing and surveillance for hepatitis E virus in the EU/EEA Operational guidance ii This report was commissioned by the European Centre for Disease Prevention and Control (ECDC), coordinated by Cornelia Adlhoch and produced by Cornelia (...) on request. Representatives of the European Food Safety Authority (EFSA, Valentina Rizzi and Michaela Hempen) and the World Health Organization Regional Office for Europe (Antons Mozalevskis) were observers in this group and received documents for review. The work was supported by two service contracts No. ECD.7600 (HEV epidemiological support – P/2017/OCS/253) and No. ID 5132 (Hepatitis B, C, and E in the EU/EEA: monitoring and testing activities). The following staff were involved on the contractor’s
The effects of message framing and healthcare provider recommendation on adult hepatitis B vaccination: A randomized controlled trial Many adults in the U.S. do not receive recommended vaccines, and the research literature remains inconclusive on the best communication strategies for increasing this behavior. This study examined the association of message framing (gained-framed vs. loss-framed vs. control), and healthcare provider (HCP) recommendation (offered vs. recommended) on uptake (...) of adult hepatitis B virus (HBV) vaccination in a high risk population using a 3 × 2 block design randomized controlled trial. Fear of shots, fear of vaccines, and perceived message framing were examined in secondary analyses. Of the 1747 participants, 47.7% (n = 833) received 0 doses of HBV vaccine, 27.8% (n = 485) received 1 dose, 10.4% received 2 doses, and 14.1% received all 3 recommended doses. There was not a significant interaction between message framing and HCP recommendation (p = .59). Mean
Immunogenicity and Safety of an Inactivated Enterovirus 71 Vaccine Administered Simultaneously With Hepatitis B Vaccine and Group A Meningococcal Polysaccharide Vaccine: A Phase 4, Open-Label, Single-Center, Randomized, Noninferiority Trial This study tested the hypothesis that the immunogenicity and safety of the simultaneous administration of enterovirus 71 (EV71) vaccine (dose 1) with recombinant hepatitis B vaccine (HepB) on day 1 and EV71 vaccine (dose 2) with group A meningococcal (...) ); or administration of HepB and MenA on days 1 and 30, respectively (the SE2 group).According to the per protocol set, antibody responses against EV71, hepatitis B virus (HBV), and group A meningococcal polysaccharide were similar regardless of administration schedule. With the non-inferiority margin setting at 10%, the seroconversion rates of the three pathogens in the SI group (100% [98.25, 100], 44.84% [38.20, 51.63] and 27.83% [21.91, 34.38]) were not inferior to those in SE1 or SE2 group (100% [98.31, 100
Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline. The Kidney Disease: Improving Global Outcomes (KDIGO) 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in chronic kidney disease (CKD) is an extensive update of KDIGO's 2008 guideline on HCV infection in CKD. This update
Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. Whether statin type influences hepatocellular carcinoma (HCC) incidence or mortality in chronic hepatitis B or C virus infection is unknown.To assess the relationship between lipophilic or hydrophilic statin use and HCC incidence and mortality in a nationwide population with viral hepatitis.Prospective propensity score (PS)-matched (...) , -7.6 to -4.2 percentage points]; aHR, 0.41 [CI, 0.32 to 0.61]), and 10-year mortality was significantly lower among both lipophilic (15.2% vs. 7.3%; RD, -7.9 percentage points [CI, -9.6 to -6.2 percentage points]) and hydrophilic (16.0% vs. 11.5%; RD, -4.5 percentage points [CI, -6.0 to -3.0 percentage points]) statin users.Lack of lipid, fibrosis, or HCC surveillance data.In a nationwide viral hepatitis cohort, lipophilic statins were associated with significantly reduced HCC incidence
Acupuncture for chronic hepatitis B. Chronic hepatitis B is a liver disease associated with high morbidity and mortality. Chronic hepatitis B requires long-term management aiming to reduce the risks of hepatocellular inflammatory necrosis, liver fibrosis, decompensated liver cirrhosis, liver failure, and liver cancer, as well as to improve health-related quality of life. Acupuncture is being used to decrease discomfort and improve immune function in people with chronic hepatitis B. However (...) , the benefits and harms of acupuncture still need to be established in a rigorous way.To assess the benefits and harms of acupuncture versus no intervention or sham acupuncture in people with chronic hepatitis B.We undertook electronic searches of the Cochrane Hepato-Biliary Group Controlled Trials Register, CENTRAL, MEDLINE, Embase, LILACS, Science Citation Index Expanded, Conference Proceedings Citation Index - Science, China National Knowledge Infrastructure (CNKI), Chongqing VIP (CQVIP), Wanfang Data
Hepatitis B Virus Infection in Pregnant Women: Screening Final Recommendation Statement: Hepatitis B Virus Infection in Pregnant Women: Screening - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 22.214.171.1248 Last Build: 5/9/2019 1:01:08 PM You are here: Final Recommendation Statement : Final Recommendation Statement Final Recommendation Statement Hepatitis B Virus Infection in Pregnant Women: Screening Recommendations made by the USPSTF are independent (...) of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services. Recommendation Summary Recommendation Summary Population Recommendation Grade Pregnant women The USPSTF recommends screening for hepatitis B virus (HBV) infection in pregnant women at their first prenatal visit To read the recommendation statement in JAMA , select . To read the evidence summary in JAMA , select . Table
What is the pathophysiology behind hepatic osteopenia/osteoporosis and who should be screened for it? Chiefs’ Inquiry Corner August 5th, 2019 – Clinical Correlations Search Chiefs’ Inquiry Corner August 5th, 2019 August 5, 2019 2 min read Patients with chronic liver disease are nearly three times more likely to develop osteoporosis than matched controls. In contrast to patients with post-menopausal osteoporosis, in whom increased osteoclast activity depletes bone density, the mechanism (...) in patients with liver disease is thought to be driven by decreased osteoblast activity. Patients with liver disease see decreases in osteoblastogenesis stimulating factors such as IGF-1 and vitamin K and increases in serum bilirubin, which directly inhibits osteoblastogenesis. It is recommended to screen the following female and male patients for hepatic osteopenia: All patients with cirrhosis All patients with chronic cholestasis (bilirubin >3mg/dL for 6 months) All potential liver transplant candidates
Screening for Hepatitis B Virus Infection in Pregnant Women: US Preventive Services Task Force Reaffirmation Recommendation Statement. Screening for hepatitis B virus (HBV) infection during pregnancy identifies women whose infants are at risk of perinatal transmission. Data from a nationally representative sample showed a prevalence of maternal HBV infection of 85.8 cases per 100 000 deliveries from 1998 to 2011 (0.09% of live-born singleton deliveries in the United States). Although (...) commissioned a reaffirmation evidence update to identify substantial new evidence sufficient enough to change the prior recommendation. The USPSTF targeted its evidence review on the effectiveness and potential harms of screening and the effectiveness and harms of case management to prevent perinatal transmission.The USPSTF previously found adequate evidence that serologic testing for hepatitis B surface antigen accurately identifies HBV infection. Interventions are effective for preventing perinatal
Radix Sophorae flavescentis versus other drugs or herbs for chronic hepatitis B. Hepatitis B virus (HBV) infection is a liver disease caused by hepatitis B virus, which may lead to serious complications such as cirrhosis and hepatocellular carcinoma. People with HBV infection may also have coinfections including HIV and other hepatitis viruses (hepatitis C or D), and coinfections may increase the risk of all-cause mortality. Chronic HBV infection increases morbidity, psychological stress (...) , and it is an economic burden on people with chronic hepatitis B and their families. Radix Sophorae flavescentis, a herbal medicine, is administered mostly in combination with other drugs or herbs. It is believed that it decreases discomfort and prevents the replication of the virus in people with chronic hepatitis B. However, the benefits and harms of Radix Sophorae flavescentis on patient-centred outcomes are unknown, and its wide usage has never been established with rigorous review methodology.To assess
Pharmacotherapies that specifically target ammonia for the prevention and treatment of hepatic encephalopathy in adults with cirrhosis. Hepatic encephalopathy is a common complication of cirrhosis, with high related morbidity and mortality. Its presence is associated with a wide spectrum of change ranging from clinically obvious neuropsychiatric features, known as 'overt' hepatic encephalopathy, to abnormalities manifest only on psychometric or electrophysiological testing, 'minimal' hepatic (...) encephalopathy. The exact pathogenesis of the syndrome is unknown but ammonia plays a key role. Drugs that specifically target ammonia include sodium benzoate, glycerol phenylbutyrate, ornithine phenylacetate, AST-120 (spherical carbon adsorbent), and polyethylene glycol.To evaluate the beneficial and harmful effects of pharmacotherapies that specifically target ammonia versus placebo, no intervention, or other active interventions, for the prevention and treatment of hepatic encephalopathy in people
Efficacy and Safety of Patient-controlled Analgesia Compared With Epidural Analgesia After Open Hepatic Resection: A Systematic Review and Meta-analysis To compare the efficacy and safety of patient-controlled analgesia (PCA) to epidural analgesia in adults undergoing open hepatic resection.Effective pain management in patients undergoing open hepatic resection is often achieved with epidural analgesia. However, associated risks have prompted investigation of alternative analgesic methods (...) was observed to be superior to PCA for pain control in patients undergoing open hepatic resection, with no significant difference in hospital length of stay, complications, or transfusion requirements. Thus, epidural analgesia should be the preferred method for the management of postoperative pain in this patient population.
An open-label, randomized, active control trial of 8 versus 12 weeks of elbasvir/grazoprevir for treatment-naive chronic hepatitis C genotype 1b patients with mild fibrosis (EGALITE): Impact of baseline viral loads and NS5A resistance-associated substitut 12-week grazoprevir/elbasvir is highly effective in hepatitis C virus genotype 1 (HCV-1) infection. The efficacy of 8-week regimen for naïve patients with mild fibrosis is elusive.HCV-1b naïve patients with mild fibrosis were randomized to 8